In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1671-1677

  Wiskirchen, Dora E ^a   Nordmann, Patrice ^b,c   Crandon, Jared L ^d   Nicolau, David P ^d  

^a UNIVERSITY OF SAINT JOSEPH   (United States)

^b Associated French National Reference Center for Antibiotic Resistance: Carbapenemase producing Enterobacteriaceae   (France)

^c University of Fribourg   (Switzerland)

^d HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CARBAPENEMASE; CEFTAZIDIME; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; NEW DELHI METALLO BETA LACTAMASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS;

EID: 84896835159     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01946-13     Document Type: Article

References (45)

1. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046-5054. http://dx.doi.org/10.1128/AAC.00774-09.
2. Shakil S, Azhar EI, Tabrez S, Kamal MA, Jabir NR, Abuzenadah AM, Damanhouri GA, Alam Q. 2011. New Delhi metallo-β-lactamase (NDM-1): an update. J. Chemother. 23:263-265. http://www.researchgate.net/publication/ 51724850-New-Delhi-metallo-lactamase-(NDM-1)-an-update.
3. Centers for Disease Control and Prevention (CDC). 2010. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb. Mortal. Wkly. Rep. 59:750. http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5924a5.htm.
4. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Uma C, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602. http://dx.doi.org/10. 1016/S1473-3099(10)70143-2.
5. Albur M, Noel A, Bowker K, MacGowan A. 2012. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56:3441-3443. http://dx.doi.org/10.1128/AAC.05682-11.
6. Poirel L, Ozdamar M, Ocampo-Sosa AA, Turkoglu S, Ozer UG, Nordmann P. 2012. NDM-1-producing Klebsiella pneumoniae now in Turkey. Antimicrob. Agents Chemother. 56:2784-2785. http://dx.doi.org/10.1128/AAC.00150-12.
7. Chan HLW, Poon LM, Chan SG, Teo JWP. 2011. The perils of medical tourism: NDM-1 positive Escherichia coli causing febrile neutropenia in a medical tourist. Singapore Med. J. 52:299-302. http://smj.sma.org.sg/5204/5204cr1.pdf.
8. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. 2011. New Delhi metallo-β-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg. Infect. Dis. 17:103-106. http://dx.doi.org/10.3201/eid1701.101358.
9. Bush K. 2013. The ABCD's of β-lactamase nomenclature. J. Infect. Chemother. 19:549-559. http://dx.doi.org/10.1007/s10156-013-0640-7.
10. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2013. Efficacy of humanized carbapenem exposures against New Delhi metallo-beta-lactamase (NDM-1) producing Enterobacteriaceae in a murine infection model. Antimicrob. Agents Chemother. 57:3936-3940. http://dx.doi.org/10.1128/AAC.00708-13.
11. Wiskirchen DE, Crandon JL, Nicolau DP. 2013. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 41:582-585. http://dx.doi.org/10.1016/j. ijantimicag.2013.02.015.
12. Clinical Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed CLSI publication M07-A9. Clinical Laboratory Standard Institute, Wayne, PA.
13. Lascols C, Peirano G, Hackel M, Laupland KB, Pitout JD. 2013. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. Antimicrob. Agents Chemother. 57:130-136. http://dx.doi.org/10.1128/AAC.01686- 12.
14. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379. (Pubitemid 28420381)
15. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-β- lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481-1486. http://dx.doi.org/10.1128/AAC.00752-06. (Pubitemid 46586832)
16. Crandon JL, Bulik CC, Nicolau DP. 2009. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352-4356. http://dx.doi.org/10. 1128/AAC.00282-09.
17. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10. 1128/AAC.00851-12.
18. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob. Agents Chemother. 57:3299-3306. http://dx.doi.org/10.1128/AAC.01989-12.
19. Onyeji CO, Bui KQ, Owens RC, Nicolau SP, Quintiliani R, Nightingale CH. 1999. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int. J. Antimicrob. Agents 12:107-114. http://dx.doi.org/10.1016/S0924-8579(98)00087-9. (Pubitemid 29276912)
20. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502. http://dx.doi.org/10.1128/AAC.01252- 07. (Pubitemid 351915681)
21. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032. http://dx.doi.org/10.1128/AAC.00372-11.
22. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22. http://dx.doi.org/10.1086/514622.
23. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501. http://dx.doi.org/10.1016/S0891-5520(03)00065- 5. (Pubitemid 38029149)
24. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081. http://dx.doi.org/10.1128/AAC.37.5. 1073. (Pubitemid 23141323)
25. Queenan AM, Shang W, Flamm R, Bush K. 2010. Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother. 54:565-569. http://dx.doi.org/10.1128/AAC.01004-09.
26. Darley E, Weeks J, Jones L, Daniel V, Wootton M, MacGowan A, Walsh T. 2012. NDM-1 polymicrobial infections including Vibrio cholera. Lancet 380:1358. http://dx.doi.org/10.1016/S0140-6736(12)60911-8.
27. Tsang KY, Luk S, Lo JY, Tsang TY, Lai ST, Hg TK. 2012. Hong Kong experiences the 'Ultimate superbug': NDM-1 Enterobacteriaceae. Hong Kong Med. J. 18:439-441. http://www.hkmj.org/abstracts/v18n5/439.htm.
28. Flateau C, Janvier F, Delacour H, Males S, Ficko C, Andriamanantena D, Jeannot K, Merens A, Rapp C. 2012. Recurrent pyelonephritis due to NDM-1 metallo-beta-lactamase producing Pseudomonas aeruginosa in a patient returning from Serbia, France, 2012. Euro Surveill. 17:pii=20311. http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=20311.
29. Mochon AB, Garner OB, Hindler JA, Krogstad P, Ward KW, Lewinski MA, Rasheed JK, Anderson KF, Limbago B, Humphries RM. 2011. New Delhi metallo-β-lactamase (NDM-1)-producing Klebsiella pneumoniae: case report and laboratory detection strategies. J. Clin. Microbiol. 49:1667-1670. http://dx.doi.org/10.1128/JCM.00183-11.
30. Roy S, Viswanathan R, Singh AK, Das P, Basu S. 2011. Sepsis in neonates due to imipenem-resistant Klebsiella pneumoniae producing NDM-1 in India. J. Antimicrob. Chemother. 66:1411-1413. http://dx.doi.org/10.1093/jac/dkr068.
31. Stone NR, Woodford N, Livermore DM, Howard J, Pike R, Mushtaq S, Perry C, Hopkins S. 2011. Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. J. Antimicrob. Chemother. 66:2677-2678. http://dx.doi.org/10.1093/jac/dkr337.
32. Chien JM, Koh TH, Chan KS, Chuah TH, Tan TT. 2012. Successful treatment of NDM-1 Klebsiella pneumoniae bacteraemia in a neutropenic patient. Scand. J. Infect. Dis. 44:312-314. http://dx.doi.org/10.3109/00365548.2011.633549.
33. Pasteran F, Albornoz E, Faccone D, Gomez S, Valenzuela C, Morales M, Estrada P, Valenzuela L, Matheu J, Guerriero L, Arbizu E, Calderon Y, Ramon-Pardo P, Corso A. 2012. Emergence of NDM-1-producing Klebsiella pneumoniae in Guatemala. J. Antimicrob. Chemother. 67:1795-1797. http://dx.doi.org/10. 1093/jac/dks101.
34. Hu H, Hu Y, Pan Y, Liang H, Wang H, Wang X, Hao Q., Yang X, Yang X, Xiao X, Luan C, Yang Y, Cui Y, Yang Rk, Gao G, Song Y, Zhu B. 2012. Novel plasmid and its variant harboring both a bla(NDM-1) gene and type IV secretion system in clinical isolates of Acinetobacter lwoffii. Antimicrob. Agents Chemother. 56:1698-1702. http://dx.doi.org/10.1128/AAC.06199-11.
35. Lowman W, Sriruttan C, Nana T, Bosman N, Duse A, Venturas J, Clay C, Coetzee J. 2011. NDM-1 has arrived: first report of a carbapenem resistance mechanism in South Africa. S. Afr. Med. J. 101:873-875. http://www.scielo.org. za/scielo.php?pid=S0256-95742011001200015&script=sci-arttext.
36. Chihara S, Okuzumi K, Yamamoto Y, Oikawa S, Hishinuma A. 2011. First case of New Delhi metallo-β-lactamase 1-producing Escherichia coli infection in Japan. Clin. Infect. Dis. 52:153-154. http://dx.doi.org/10.1093/cid/ciq054.
37. NDM-1 in Raoultella ornithinolytica. Antimicrob. Agents Chemother. 57:1092-1093. http://dx.doi.org/10.1128/AAC.02147-12.
38. Sidjabat H, Nimmo GR, Walsh TR, Binotto E, Htin A, Hayashi Y, Li J, Nation RL, George N, Paterson DL. 2011. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi metallo-β-lactamase. Clin. Infect. Dis. 52:481-484. http://dx.doi.org/10.1093/cid/ciq178.
39. Hoang TH, Wertheim H, Minh NB, Duong TN, Anh DD, Phuong TT, Son TH, Izumiya H, Ohnishi M, Shibayama K, Hien NT. 2013. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains containing New Delhi metallo-beta-lactamase isolated from two patients in Vietnam. J. Clin. Microbiol. 51:373-374. http://dx.doi.org/10.1128/JCM.02322-12.
40. Poirel L, Benouda A, Hays C, Nordmann P. 2011. Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco. J. Antimicrob. Chemother. 66:2781-2783. http://dx.doi.org/10.1093/jac/dkr384.
41. Samuelsen O, Thilesen CM, Heggelund L, Vada AN, Kummel A, Sundsfjord A. 2011. Identification of NDM-1-producing Enterobacteriaceae in Norway. J. Antimicrob. Chemother. 66:670-683. http://dx.doi.org/10.1093/jac/dkq483.
42. Peirano G, Ahmed-Bentley J, Woodford N, Pitout J. 2011. New Delhi metallo-β-lactamase from traveler returning to Canada. Emerg. Infect. Dis. 17:242-244. http://dx.doi.org/10.3201/eid1702.101313.
43. Hrabak J, Stolbova M, Studentova V, Fridrichova M, Chudackova E, Zemlickova H. 2012. NDM-1 producing Acinetobacter baumannii isolated from a patient repatriated to the Czech Republic from Egypt, July 2011. Euro Surveill. 17:pii=20085. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20085.
44. Oteo J, Domingo-Garcia D, Fernandez-Romero S, Saez D, Guiu A, Cuevas O, Lopez-Brea M, Campos J. 2012. Abdominal abscess due to NDM-1-producing Klebsiella pneumoniae in Spain. J. Med. Microbiol. 61:864-867. http://dx.doi.org/10.1099/jmm.0.043190-0.
45. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.